Last reviewed · How we verify
Meningococcal (vaccine)
The meningococcal vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis, preventing meningococcal disease.
The meningococcal vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis, preventing meningococcal disease. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y, Prevention of meningococcal meningitis and septicemia.
At a glance
| Generic name | Meningococcal (vaccine) |
|---|---|
| Also known as | Meningitec, NeisVacC, Menitorix, Menveo, Nimenrix, Menomune |
| Sponsor | GlaxoSmithKline |
| Drug class | Bacterial polysaccharide conjugate vaccine |
| Target | Neisseria meningitidis capsular polysaccharides and outer membrane proteins |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Meningococcal vaccines contain antigens derived from the bacterial capsule or outer membrane proteins of Neisseria meningitidis. Upon administration, these antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory B cells. This immune priming enables rapid recognition and neutralization of the pathogen upon natural exposure, preventing invasive meningococcal disease including meningitis and septicemia.
Approved indications
- Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y
- Prevention of invasive meningococcal disease in infants, children, adolescents, and adults
Common side effects
- Injection site pain, erythema, or swelling
- Fever
- Headache
- Myalgia or fatigue
- Nausea
Key clinical trials
- Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection (PHASE2)
- Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections (PHASE3)
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) (PHASE4)
- Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China (PHASE3)
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- Long-Term PF-06651600 for the Treatment of Alopecia Areata (PHASE3)
- R21/Matrix-M in African Children Against Clinical Malaria (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meningococcal (vaccine) CI brief — competitive landscape report
- Meningococcal (vaccine) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI